NEW YORK, March 13, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla
Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc.
(NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and
IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private
wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Northwest Biotherapeutics, Inc.
Analyst Notes
On March 10, 2014, Northwest
Biotherapeutics, Inc. (NW Bio) announced that the Paul Ehrlich
Institute (PEI - the FDA of Germany) has approved the Company of a
'Hospital Exemption' early access program under Section 4b of the
German Drug Law. According to NW Bio, under the exemption, it may
provide DCVax-L, outside of the Company clinical trial and charge
full price to patients for the treatment of any glioma brain
cancers, both newly diagnosed and recurrent. NW Bio also stated
that the German reimbursement authority (Institut Für Das
Entgeltsystem Im Krankenhaus or InEK) has determined that DCVax-L
treatments for glioma brain cancers are eligible to obtain
reimbursement from the Sickness Funds (health insurers) of the
German healthcare system. Commenting on the approval, Linda Powers, CEO of NW Bio, stated, "We are
grateful to the PEI and InEK for these important decisions enabling
DCVax-L to be made available to brain cancer patients now, and
enabling reimbursement to be arranged with the Sickness Funds." The
full analyst notes on Northwest Biotherapeutics, Inc. are available
to download free of charge at:
http://www.AnalystsReview.com/03132014/NWBO/report.pdf
--
La Jolla Pharmaceutical Co. Analyst
Notes
On March 10, 2014, La Jolla
Pharmaceutical Co. (La Jolla) announced positive top-line results
from its randomized, placebo-controlled Phase 2 trial of GCS-100 in
chronic kidney disease (CKD). According to La Jolla, the trial met
its primary efficacy endpoint of a statistically significant
improvement in kidney function. According to the Company, GCS-100
was well tolerated and 117 out of the 121 patients enrolled,
completed the treatment. Commenting on the results, George Tidmarsh, M.D., Ph.D., President and CEO
of La Jolla, stated, "We want to thank the patients who volunteered
for this study and our excellent group of investigators for their
hard work completing this Phase 2 trial in a timely fashion. We are
obviously delighted with the results. We hope to use these results
as a platform for further investigation not only in chronic kidney
disease but also in other diseases where tissue fibrosis plays a
central role." The full analyst notes on La Jolla Pharmaceutical
Co. are available to download free of charge at:
http://www.AnalystsReview.com/03132014/LJPC/report.pdf
--
Merrimack Pharmaceuticals, Inc.
Analyst Notes
On March 10, 2014, Merrimack
Pharmaceuticals, Inc.'s (Merrimack Pharmaceuticals) stock reflected
an increase of 8.84% at $5.91. Over
the past six months trading period, the Company's stock went up by
41.39%, compared to the Nasdaq Composite Index which went up by
16.95% during the same trading period. The full analyst notes on
Merrimack Pharmaceuticals, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03132014/MACK/report.pdf
--
Rosetta Genomics, Ltd. Analyst
Notes
On March 3, 2014, Rosetta
Genomics, Ltd. (Rosetta Genomics) announced that data from a study
of the Company's microRNA technology was published online in the
American Journal of Cardiology in an article titled,
"Relation of Reduced Expression of MiR-150 in Platelets to
Atrial Fibrillation in Patients With Chronic Systolic Heart
Failure." According to the Company, the aim of the study was to
evaluate the potential association of miRNAs in platelets with
atrial fibrillation (AF) in patients with chronic systolic heart
failure (HF). Kenneth A. Berlin, President and CEO of Rosetta Genomics,
stated, "We are encouraged by the publication of these important
data, which, along with our earlier study published in the European
Journal of Heart Failure in 2012, support our continued research
efforts in the area of blood-based microRNA biomarkers in order to
advance new assays for the early diagnosis and refined risk
stratification of heart failure patients. We plan to perform
additional studies aimed at further examining the expression of
identified miRNA biomarkers in various blood fractions and
anticipate launching a new assay related to this area in 2017." The
full analyst notes on Rosetta Genomics, Ltd. are available to
download free of charge at:
http://www.AnalystsReview.com/03132014/ROSG/report.pdf
--
IntelliPharmaCeutics International
Inc. Analyst Notes
On March 4, 2014,
IntelliPharmaCeutics International Inc. (Intellipharmaceutics)
announced that it is scheduled to present at the 13th Annual
Needham Healthcare Conference. According to the Company, the
conference is scheduled at 3:00 p.m.
EDT on April 8, 2014 at The
Westin Grand Central Hotel, New
York. Additionally, Intellipharmaceutics stated that the
presentation will be made available via a live webcast and may be
accessed through the Company's website under Investor Relations'
Events and Presentations section. The full analyst notes on
IntelliPharmaCeutics International Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03132014/IPCI/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to
leverage our economy of scale. Most investors do not have time to
track all publicly traded companies, much less perform an in-depth
review and analysis of the complexities contained in each
situation. That's where Analysts Review comes in. We provide a
single unified platform for investors' to hear about what matters.
Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review